Navigation Links
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Date:2/28/2011

(p<0.0001)

0.34

(72% reduction)

(p<0.0001)Key secondary endpointsProportion of patients with greater than or equal to 1 flare (% reduction compared to placebo) 56.1%

25.6%

(54% reduction)

(p=0.0001)

20.5%

(63% reduction)

(p<0.0001)Proportion of patients with  greater than or equal to 2 flares (% reduction compared to placebo)32.9%

8.5%

(74% reduction)

(p=0.0002)

6.0%

(82% reduction)

(p<0.0001)* One patient did not report flare data and was excluded from efficacy analyses Overall, the cumulative rate of infections was 27.4% in patients treated with ARCALYST 160 mg, 28.0% in patients treated with ARCALYST 80 mg, and 25.6% in placebo patients.  No deaths were reported in this study.

Specific adverse events that occurred at a frequency of at least 5% in any study group were: injection site reaction (17.9% with ARCALYST 160 mg, 12.2% with ARCALYST 80 mg, and 1.2% with placebo), upper respiratory tract infection (15.5% with ARCALYST 160 mg, 12.2% with ARCALYST 80 mg, and 12.2% with placebo), influenza viral infection (6.0% with ARCALYST 160 mg, 6.1% with ARCALYST 80 mg, and 7.3% with placebo), taking more than the recommended dose (4.8% with ARCALYST 160 mg, 7.3% with ARCALYST 80 mg, and 2.4% with placebo), and headache (1.2% with ARCALYST 160 mg, 6.1% with ARCALYST 80 mg, and 3.7% with placebo).

About the PRE-SURGE 1 StudyRegeneron previously announced the results of the identical North American-based PRE-SURGE 1 (PREventative Study against URate-lowering drug-induced Gout Exacerbations) study, a double-blind, placebo-controlled study which evaluated the number of gout flares per patient over the first 16 weeks following initiation of allopurinol therapy.  Patients who received ARCALYST at a weekly, self-administered, subcutaneous dose of 160 mg had an 80% decrease in mean numbe
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
2. New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays
3. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
7. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
9. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
10. MADIT-CRT Trial Meets Primary Endpoint
11. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
(Date:1/14/2014)... 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - ... instrumentation to place and insert the screw accurately - ... (e.g. ligament) repair or reconstruction as it holds the ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC ...
(Date:1/14/2014)... , Jan. 14, 2014 NineSigma , Inc., ... its Innovation Leadership Summit , May 14-16, 2014 ... Cleveland Ohio . This ... organizations committed to breakthrough achievements through open innovation. Participants ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... Japanese Study Suggests the Drug Improves Memory, SARASOTA, ... announced today that it has received positive,preliminary results ... a,promising new drug application for the treatment of ... in,September, is the first human clinical study conducted ...
... treated with maximally,tolerated lipid-lowering therapies experienced 50% ... other atherogenic,when treated with 300 mg/week ISIS ... 26, 2007,/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced,results ... of ISIS 301012 in,patients with homozygous familial ...
Cached Medicine Technology:Sarasota's Roskamp Institute Announces Positive Safety Data in,Human Clinical Study for Alzheimer's Disease 2Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 2Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 3Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 4Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 5Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 6
(Date:4/18/2014)... news release is available in French . ... could revolutionize surgical practice and regenerative medicine. A team ... et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from ... Paris 13), has just demonstrated that the principle of ... in vivo to repair soft-tissue organs and tissues. This ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... CHAMPAIGN, Ill. One of the most popular vaccine ... choice. And doctors may be overlooking some cost factors ... actually a more expensive option, according to a new ... of vaccines to administer can be driven by numerous ... study and a professor of computer science and of ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... have a decreased risk of developing diabetes, according to ... The study found that// only 8 percent of the ... percent of those on older drugs. ,The ... Norvasc and Coversyl with a beta-blocker and a diuretic. ...
... The Journal of the American Medical Association finds that ... as ever. Doctors' training, or// residency includes shifts that ... Council for Graduate Medical Education (ACGME) say that they ... MPH, of Harvard Medical School, and colleagues said that ...
... the September issue of Archives of Pediatrics & Adolescent Medicine, ... prepared in the event of a conflict// and have trained ... need urgent medical care. The report is based on the ... ,Military hospitals are likely to encounter injured children as wars ...
... of Japan, who gave birth to a male heir today, ... for transplantation to leukemia patients, Masao// Nakabayashi, director of Aiiku ... Princess Kiko made the offer after she gave birth by ... on her request," Nakabayashi told reporters. Experts say that the ...
... leader in oral care, in association with the Indian ... observed as Oral Health Month. Now in its third ... oral health awareness campaign in India to establish and ... all ages. This year, the theme of Oral Health ...
... the pizza melts away in your mouth, you might just ... in this delicious spread.// A novel study has served the ... calorie content of fast-food meals. Although the estimations were accurate ... ,Pierre Chandon, a co-author of the study ...
Cached Medicine News:Health News:Military Hospitals Need To Be Prepared To Treat Children 2Health News:Striving to Make India Free from Tooth Decay 2
Inquire...
The Diagnostic Automation, Inc. (DAI) Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the in vitro determination of IgM antibody to Measles in human serum....
... For over 30 years, Digisonics has ... workstations with the first review station, ... management, and the best multi-modality reporting., ... performance image review workstations, professional reporting ...
... glucocorticoid produced by the adrenal cortex in ... secreted with a circadian periodicity, and peaks ... Cortisol is often elevated in major depressive ... and in the visceral fat of obese ...
Medicine Products: